This is a report produced using the OpenSAFELY Platform by: University of Surrey
A national audit of pancreatic enzyme prescribing in pancreatic cancer
- Description
- This dashboard shows prescribing of pancreatic enzyme replacement therapy (PERT) for people with unresectable pancreatic cancer in England
- Authors
- Agnieszka Lemanska, Colm Andrews, Louis Fisher, Benjamin Butler-Cole, Amir Mehrkar, Keith J Roberts, Ben Goldacre, Alex J Walker, Brian MacKenna
- Contact
- Get in touch and tell us how you use this report or new features you'd like to see: team@opensafely.org
- First published
- 15 Jan 2023
- Last released
- 07 Jun 2024
- DOI
- http://doi.org/10.53764/rpt.a0b1b51c7a
- Links
This is a report produced using the OpenSAFELY Platform by: University of Surrey
This dashboard is hosted on the OpenSAFELY Reports website on behalf of the University of Surrey
PERT prescribing in pancreatic cancer
a.lemanska@surrey.ac.uk
First created January 2023
Produced using OpenSAFELY-TPP
Last updated June 2024
Updated 3-monthly, next update due: September 2024
The full text of this study has been published here
Index
Abstract
Background: Cancer treatments were variably disrupted during the COVID-19 pandemic. Despite UK national guidelines recommending pancreatic enzyme replacement therapy to all people with unresectable pancreatic cancer, observational studies demonstrate under-prescribing
Aim: To investigate the impact of the COVID-19 pandemic on the prescribing of pancreatic enzyme replacement to people with unresectable pancreatic cancer.
Methods: With the approval of NHS England, we conducted a cohort study using 24 million health records through the OpenSAFELY-TPP research platform. We modelled prescribing rates from January 2015 and investigated the effect of the pandemic with multivariable linear regression.
Results We found no reduction in pancreatic enzyme replacement therapy during the COVID-19 pandemic. Overall, since 2015, the rates of prescribing increased steadily over time by 1% every year. The national rates ranged from 41% in 2015 to 50% in 2024. There was substantial regional variation. The highest rates of 50% to 60% were in the West Midlands.
Conclusions: The COVID-19 pandemic did not affect PERT prescribing in unresectable pancreatic cancer. Although overall rates increased over time, substantial under-prescribing persisted. At around 50% in 2024, the rates were still below the recommended 100% standard. Despite the national guidelines, under-prescribing of PERT continued and has improved only marginally since their publication. This could be an important missed opportunity to reduce morbidity for patients with pancreatic cancer. The research into barriers to prescribing of PERT and geographic variation is urgently needed to improve quality of care.
National rates
Figure 2 shows the rates in prescribing over time in England. Overall, the COVID-19 pandemic did not affect PERT prescribing to people with unresectable pancreatic cancer.
In view of the national target rate of 100%, at around 50% in 2024, the prescribing rates were still below the recommended standard. (Figure 2).
Regional rates
Figure 3 shows the rates in prescribing by regions in England. The highest rates, achieving values between 50% and 60% from 2018 onwards were in the West Midlands region. Please note, data for London is limited in this dataset and therefore the representativeness of figures for London is limited and difficult to assess.